Comparing Effects of Dapagliflozin and Semaglutide on Epicardial Fat in Adults with Heart Attack

What this Trial Is About

Heart disease remains the leading cause of death worldwide, with ischemic heart disease as the primary contributor. This study focuses on patients with ST-segment elevation myocardial infarction STEMI and non-ST-segment elevation myocardial infarction NSTEMI to evaluate the effects of two drugs on epicardial fat, which is linked to the risk of heart events. The trial particularly looks at how these drugs influence epicardial fat volume, a factor connected to cardiovascular risks, especially in patients with type 2 diabetes and obesity. The trial compares dapagliflozin, given as a 10 mg daily oral tablet, against semaglutide, starting at 3 mg and gradually increasing to 14 mg daily, over a 12-month treatment period. Epicardial fat will be measured using coronary tomography at the time of initial hospitalization and after one year of treatment. Participants include adults over 18 years old diagnosed with STEMI or NSTEMI, with or without type 2 diabetes and clinical obesity. During the study, patients will be monitored for medication adherence and tolerability following standard treatment guidelines. Assessments include measuring epicardial fat volume, changes in LDL cholesterol, blood sugar control fasting glucose and HbA1c, body weight, and major adverse cardiovascular events over 12 months. This trial seeks to understand how these medications affect heart fat and overall cardiovascular risk in this patient group.

Epicardial Cardiac Fat-CT (EPIC-CT)